By Laura Tamayo泭
Amyotrophic lateral sclerosis (ALS) is rare but fatal. Affecting , the illness advances very quickly. Most patients die between two and five years after their diagnoses. ALS has no cure, but experimental treatments could shift the futures of patients with the disease.泭泭
Zaghloul Ahmed, and chair of the Physical Therapy Department at the College of Staten Island, has conducted research for more than two decades. His work investigates how electrical stimulation can influence neural circuits and improve motor function. This could help people with conditions such as spinal cord injury, stroke, and neurodegenerative diseases. In 2014, he founded the company .泭
ALS impairs neuronal tissue and muscle, ���affecting motor��� capacities. Neurons transmit impulses from the brain to muscles. As ALS worsens, the neurons degrade. Controlling one���s movements becomesincreasingly difficult. The dormant areas of the body, no longer receiving and responding to signals from the brain, can weaken and eventually atrophy.泭泭
���The reason we���re called Pathmaker is… the movement really starts in your brain,��� says Ahmed. ���You think the intended movement, the signal goes down… and then the movement is generated. In neuroscience, we call it ���pathway.������泭
For Ahmed, illuminated the relationship between stimulation and neuroplasticity. He discovered that stimulation from several bodily regions can normalize dysfunctional neural pathways.泭
Ahmed also found a gap between his findings and patients��� experiences. People who needed care couldn���t access his discoveries. Academic research began to feel insufficient to fight ALS, so Ahmed came up with the idea for a company. He reached out to entrepreneurs and medical device experts to shift into the business world.泭泭
Pathmaker Neurosystems��� can target and provoke nerve movement in different parts of the spinal cord. The spinal cord is key, because it delivers signals from the brain to the body. The current���s direction of flow can determine whether it suppresses or excites nerves. With ALS, tissue that has overly-excited nerves needs a current that flows from a positive to a negative source, which will suppress those nerves and keep the tissue alive.泭
The product is in clinical trials. ������The study administers the MyoRegulator device to 15 people with ALS, each receiving four weeks of treatment and six months of assessments. The U.S. Department of Defense���s funds the project.泭
The study measures neurons��� sensitivity to firing, protein levels in patients��� blood, and how those patients describe their functioning and quality of life. This fall and winter, Pathmaker Neurosystems hopes to present their final results at two leading ALS conferences: the in Clearwater, Florida, and the in Amsterdam.泭
The clinical trials also measure how comfortable the device is for patients. Ahmed says that translating research into a product requires extensive repetition, especially when the stakes are so high. It will require long and repeated clinical trials with humans to fully determine the product���s impact on ALS patients’ health.泭泭
���������While currently focused on spinal-cord stimulation, Pathmaker Neurosystems is applying for grants to expand their methods to the brain. ������This could have important implications for the study and treatment of dementia at large. Ahmed and his partners are eager to discover in what realms of health their technologies might intervene.泭
���While ALS remains our immediate priority due to the urgent unmet need,��� says Ahmed. ���The broader potential of this platform remains an exciting area.���泭
